A Phase 1/2 interventional study of Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 and TIV mRNA-neuraminidase (NA) in Influenza and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 24 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 25th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 1/2, and was the 131st registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:
Sanofi · Sites in Poland
Ages 60+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
Sanofi · Sites in United States
Ages 18+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 47 · Phase 3 35 · Phase 4 33
First in 2003; this study’s year is marked. 3 started in 2025.
This study's enrollment of 1,162 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 305 across the 126 interventional studies, 1,001 across the 13 observational. Of the 133 that completed or were terminated, 73 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
2 of the studies in Influenza, Human by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907511SanofiStudy to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 2026-12-01 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Influenza, Human by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
Study details include the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
OR
A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours prior to administration of study intervention.
Exclusion Criteria:
Participants are not eligible for the study if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 1)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 2)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 3)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 4)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 5)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of hexavalent influenza mRNA vaccine composed of differing dose levels of TIV mRNA-HA Vaccine 1 in combination with TIV mRNA-NA (Combination 6)
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 · Biological: TIV mRNA-neuraminidase (NA)
Participants will receive a single dose of TIV mRNA-HA Vaccine 1
Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Participants will receive a single dose of TIV mRNA-NA
Biological: TIV mRNA-neuraminidase (NA)
Participants will receive single dose of TIV mRNA-HA Vaccine 2
Biological: TIV mRNA-HA Vaccine 2
Participants will receive single dose of QIV-SD vaccine (for participants 50 to 64 years of age only)
Biological: Quadrivalent Influenza Standard Dose Vaccine
Participants will receive single dose of QIV-HD vaccine
Biological: Quadrivalent Influenza Vaccine High Dose
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
* Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection
* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection
Also known as: Fluzone Qudrivalent®
* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection
Also known as: Fluzone High-Dose Quadrivalent®
Number of participants with immediate unsolicited systemic adverse events (AEs)
Unsolicited systemic AEs that occur within 30 minutes after vaccination
Time frame: Within 30 minutes after injection
Number of participants with solicited injection site reactions
Solicited injection site reactions pre-listed in the participant diary and in the case report form CRF
Time frame: Up to 7 days after injection
Number of participants with solicited systemic reactions
Solicited systemic reactions pre-listed in the participant diary and in the CRF
Time frame: Up to 7 days after injection
Number of participants with unsolicited AEs
AEs that do not fulfill the conditions of solicited reactions
Time frame: Up to 28 days after injection
Number of participants with medically attended adverse events (MAAEs)
MAAEs reported up to 180 days after injection
Time frame: Up to 180 days after injection
Number of participants with serious adverse events (SAEs)
Throughout the study
Time frame: SAEs throughout the study (Up to approximately 12 months)
Number of participants with adverse events of special interest (AESIs)
Throughout the study
Time frame: AESIs throughout the study (Up to approximately 12 months)
Number of participants with out-of-range biological test results
Out-of-range biological test results (including shift from baseline values)
Time frame: Up to 8 days after injection
Hemagglutinin inhibition (HAI) titers
HAI titers at D01 and D29
Time frame: At Day 1 and Day 29
Individual HAI antibody (Ab) titer ratio D29/D01
Individual HAI Ab titer ratio D29/D01
Time frame: At Day 1 and Day 29
Seroconversion (HAI Ab titer)
Number of participants with HAI Ab titer \< 10 \[1/dil\] at Day 1 and post-injection titer ≥ 40 \[1/dil\] at Day 29, or titer ≥ 10 \[1/dil\] at Day 1 and a ≥ 4-fold increase in titer \[1/dil\] at Day 29
Time frame: At Day 1 and Day 29
HAI Ab titer ≥ 40 (1/dil)
HAI Ab titer ≥ 40 (1/dil) at D29
Time frame: At Day 29
Neuraminidase inhibition (NAI) titers
NAI titers at D01 and D29
Time frame: At Day 1 and Day 29
Individual NAI Ab titer ratio D29/D01
Individual NAI Ab titer ratio D29/D01
Time frame: At Day 1 and Day 29
Seroconversion (NAI Ab titer)
Number of participants with NAI Ab titer \< 10 \[1/dil\] at D01 and post-injection titer ≥ 40 \[1/dil\] at D29, or titer ≥ 10 \[1/dil\] at D01 and a ≥ 4-fold increase in titer \[1/dil\] at D29)
Time frame: At Day 1 and Day 29
NAI Ab titer ≥ 40 (1/dil)
NAI Ab titer ≥ 40 (1/dil) at D29
Time frame: At Day 29
2-fold and 4-fold rise in NAI titers
2-fold and 4-fold rise in NAI titers from D01 to D29
Time frame: Day 1 to Day 29
Neutralizing antibodies titers
Neutralizing antibodies titers at D01 and D29
Time frame: At Day 1 and Day 29
Individual neutralizing antibodies titer ratio
Individual neutralizing antibodies titer ratio D29/D01
Time frame: At Day 1 and Day 29
2-fold and 4-fold increase in neutralizing titers
2-fold and 4-fold increase in neutralizing titers D01 through D29
Time frame: Day 1 to Day 29
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jan 2025 to primary completion in May 2026, 16 months.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →